Press

Field Trip Health & Wellness Ltd. to Release Fiscal 2023 Third Quarter Financial Results on Tuesday, February 28, 2023

Feb 21 • 2 min read

Field Trip Health & Wellness Ltd. (TSXV: FTHW OTCQB: FTHWF), a global leader in the delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 third quarter ended December 31, 2022, after market close on Tuesday, February 28, 2023. In addition, the Company announced that its Board of…

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

Feb 21 • 7 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW | OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188 (“N,N-Dimethyltryptamine or DMT”). AGN Neuro plans to be the first company globally…

Numinus Expands Research Capabilities with new Phoenix Clinical Research Site

Feb 17 • 3 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has expanded its clinical research capabilities into Arizona. The site, located in Phoenix where Numinus operates mental health clinics, is Numinus’ third clinical trial research site in the US, and fifth research site overall….

Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights

Feb 17 • 6 min read

Cybin Inc. (NEO:CYBN | NYSE American:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today reported unaudited financial results for its third quarter ended December 31, 2022, and recent business highlights. “Looking ahead, we remain well-positioned to deliver on multiple near-term clinical milestones and data catalysts across our pipeline programs. With interim data expected imminently…

FSD Pharma Inc. Receives Confirmation of NASDAQ Compliance

Feb 17 • 2 min read

FSD Pharma (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has regained compliance with NASDAQ continued listing requirements. The company announced that it has received confirmation from the exchange that it…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436